Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.0152W HIGH $23.68
Volume
52.56 K
Value Traded
2.71 M
Short % Float
5.47%
-2.17%Week
-4.37%1 Month
-6.87%3 Month
+20.9%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
458.17 M
EPS (TTM)
0.26
P/E Ratio
76.77
Ent. Value
544.87 M
Total Shares
22.52 M
Float Shares
12.53 M
Insiders
43.34%
Institutions
48.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NRC Catalyst Timeline
Dated clinical, regulatory and corporate events for National Research Corporation Common Stock (Delaware)
Catalyst Timeline
Dated clinical, regulatory & corporate events for National Research Corporation Common Stock (Delaware)
63Total events
0Upcoming
1Tier-1 (high impact)
2009 to 2026Coverage
Event history 50
●Quarterly UpdateCorporate
Board declares quarterly dividend of $0.10 per Class A share and $0.60 per Class B share
●Quarterly UpdateCorporate
National Research Corporation announces third quarter 2016 results
●Quarterly UpdateCorporate
Reaffirmed suspension of cash dividends for investment in Customer Connect
●Quarterly UpdateCorporate
National Research Corporation announces first quarter 2013 results
▲Quarterly UpdateCorporate
National Research Corporation announces second quarter 2012 results
●Quarterly UpdateCorporate
National Research Corporation announces first quarter 2012 results
Past FDA Catalysts and PDUFA Decisions
How NRC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NRC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rau Jason RussellOfficer (Executive Vice President) | Acquisition | 60,000 60,000 held | $0.00 | 03/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NRC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NRC for Q2 2026. | ||||
NRC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NRC ranks across every disease it competes in
Competitive Position is a premium feature
See how NRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNRC News
-NRC
Sep 24, 2026GlassesUSA.com and Renowned Ophthalmologist Norman A. Saffra, MD, FAAO, Launch Vision Education Hub Backed by New National Research
GlassesUSA.com has launched a new vision education hub in collaboration with Dr. Norman A. Saffra to address common consumer questions about eyewear and eye health. The initiative follows research indicating significant uncertainty among glasses wearers regarding their prescriptions and eye care. The hub offers expert-led videos and practical guides to help consumers make informed decisions about their vision.
Read more →-NRC
Sep 1, 2026Brain Aneurysm Foundation Marks Brain Aneurysm Awareness Month with National Research, Education and Community Initiatives
The Brain Aneurysm Foundation (BAF) is celebrating Brain Aneurysm Awareness Month with a series of initiatives, including its 20th Annual Research Grant Symposium in Louisville, where it will award $650,000 to support 18 research projects. The month features community events, public awareness campaigns, and advocacy efforts aimed at improving detection and treatment of brain aneurysms. BAF has invested over $7 million in research since 2007, highlighting its commitment to advancing understanding and care in this field.
Read more →-NRC
Jul 28, 2026▼ -18.1%on this news
NRC Health Announces Second Quarter 2026 Results
NRC Health reported strong second quarter results for 2026, highlighting significant growth in TRCV compared to the previous year. The company showcased effective execution in its market strategies and product delivery. Additionally, it achieved the highest bookings for The Governance Institute in seven years, indicating a robust position for future growth.
Read more →-NRC
Apr 28, 2026NRC Health Announces First Quarter 2026 Results
NRC Health reported a strong start to 2026, achieving a 4% increase in revenue to $34.8 million and a notable rise in Total Recurring Contract Value by 13%. The company also declared a quarterly cash dividend of $0.16 per share. CEO Trent Green emphasized the significance of their largest deal in history as a validation of their strategic direction.
Read more →-NRC
Mar 4, 2025NATIONAL RESEARCH CORPORATION APPOINTS TRENT GREEN AS CHIEF EXECUTIVE OFFICER
National Research Corporation (NRC) has announced the appointment of Trent Green as the new Chief Executive Officer, effective June 1, 2025. Green, who has over 25 years of experience in healthcare leadership, will succeed Mike Hays, who will transition into the role of Chairman. With a vision for expanding NRC Health's capabilities, Green aims to enhance the healthcare experience through innovative, data-driven solutions. This leadership change marks a continued commitment to NRC’s mission of humanizing healthcare and improving outcomes for patients and providers.
Read more →-NRC
Nov 7, 2017Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2017 RESULTS LINCOLN, Nebraska (
Contact: Kevin R. Karas Chief Financial Officer NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2017 RESULTS LINCOLN, Nebraska (November 7, 2017) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the third quarter of 2017. Net New Sa
Read more →-NRC
Aug 30, 2017Q " Street Lincoln , NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin Karas Chief Financial Officer 402-475-2525 WARDEN RETIRES FROM NATIONAL RESEARCH CORPORATION BOARD OF DIRECTORS LINCOLN, Nebraska (
NATIONAL RESEARCH CORPORATION BOARD OF DIRECTORS LINCOLN, Nebraska (August 30, 2017) - National Research Corporation (NASDAQ: NRCIA and NRCIB) Board of Directors member Gail L. Warden announced his retirement from the board effective today. Mr. Warden has served as a director o
Read more →-NRC
Aug 1, 2017Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2017 RESULTS LINCOLN, Nebraska (
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2017 RESULTS LINCOLN, Nebraska (August 1, 2017) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the second quarter of 201
Read more →-NRC
May 2, 2017Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIR ST QUARTER 2017 RESULTS LINCOLN, Nebraska (
1245 "Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2017 RESULTS LINCOLN, Nebraska (May 2, 2017) - National Research Corporation (NASDAQ: N
Read more →-NRC
Feb 14, 2017Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2016 RESULTS Board of Dir
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2016 RESULTS Board of Directors Declares Quarterly Dividend LINCOLN, Nebraska (February 14, 2017) - National Research Corporation (NASDAQ: NRCIA
Read more →-NRC
Nov 1, 2016Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2016 RESULTS LINCOLN, Nebraska (
Contact: Kevin R. Karas Chief Financial Officer NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2016 RESULTS LINCOLN, Nebraska (November 1, 2016) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the third quarter of 2016. Remarking
Read more →-NRC
Aug 2, 2016Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2016 RESULTS LINCOLN, Nebraska (
1245 "Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2016 RESULTS LINCOLN, Nebraska (August 2, 2016) - National Research Corporation (NASDA
Read more →-NRC
May 3, 2016Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2016 RESULTS LINCOLN, Nebraska (
Contact: Kevin R. Karas Chief Financial Officer NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2016 RESULTS LINCOLN, Nebraska (May 3, 2016) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the first quarter of 2016. Remarking on Co
Read more →-NRC
Feb 9, 2016Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2015 RESULTS Board of Dir
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2015 RESULTS Board of Directors Declares Quarterly Dividend LINCOLN, Nebraska (February 9, 2016) - National Research Corporation (NASDAQ: NRCIA a
Read more →-NRC
Nov 3, 2015Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2015 RESULTS LINCOLN, Nebraska (
1245 "Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES THIRD QUARTER 2015 RESULTS LINCOLN, Nebraska (November 3, 2015) - National Research Corporation (NASDA
Read more →-NRC
Oct 28, 2015Kevin Karas Chief Financial Officer National Research Corporation 800-388-4264 kkaras@nationalresearch.com National Research Appoints Healthcare Visionary, Dr. Donald Berwick, to its Board
Chief Financial Officer National Research Corporation kkaras@nationalresearch.com National Research Appoints Healthcare Visionary, Dr. Donald Berwick, to its Board of Directors Lincoln, Nebraska, October 27, 2015 - Today, National Research Corporation (NASDAQ: NRCIA and NRCIB
Read more →-NRC
Oct 1, 2015Kevin Karas Chief Financial Officer National Research Corporation 800-388-4264 kkaras@nationalresearch.com FOR IMMEDIATE RELEASE National Research Corporation Announces the Promotion of Steve Jackson to Presiden
National Research Corporation Announces the Promotion of Steve Jackson to President Lincoln, Nebraska, October 1, 2015 - Today, National Research Corporation (NASDAQ: NRCIA and NRCIAB) announced the promotion of Steve Jackson to the position of President. Mr. Jackson will work a
Read more →-NRC
Aug 4, 2015NRC Announces Second Quarter 2015 Results
Contact: Kevin R. Karas Chief Financial Officer NATIONAL RESEARCH CORPORATION ANNOUNCES SECOND QUARTER 2015 RESULTS LINCOLN, Nebraska (August 4, 2015) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the second quarter of 2015. Remarking
Read more →-NRC
May 7, 2015Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2015 RESULTS __________________________
Contact: Kevin R. Karas Chief Financial Officer NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER 2015 RESULTS __________________________________________ LINCOLN, Nebraska (May 7, 2015) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for
Read more →-NRC
Feb 10, 2015Q" Street Lincoln, NE 68508 Phone: 402-475-2525 Fax: 402-475-9061 Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2014 RESULTS LINCOLN, Neb
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 2014 RESULTS LINCOLN, Nebraska (February 10, 2015) - National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced results for the fourt
Read more →About National Research Corporation Common Stock (Delaware)
Headquarters1245 Q STREET, LINCOLN, NE, 68508
BIOPHARMAWATCH ELITE PLUS
Trade the next NRC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime